

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : A61K 31/40, C07D 209/14	A1	(11) International Publication Number: WO 89/ 04659 (43) International Publication Date: 1 June 1989 (01.06.89)
(21) International Application Number: PCT/EP88/01059 (22) International Filing Date: 21 November 1988 (21.11.88) (31) Priority Application Number: 8727099 (32) Priority Date: 19 November 1987 (19.11.87) (33) Priority Country: GB (71) Applicant (for all designated States except US): CELLENA (CELL ENGINEERING) A.G. [CH/CH]; Lohwisstrasse 50, CH-8123 Ebmatingen (CH). (72) Inventors; and (75) Inventors/Applicants (for US only): PIERPAOLI, Walter [IT/CH]; Via Luserte, 2, CH-6572 Quartino-Magadino (CH). MAESTRONI, Giorgio [IT/IT]; Via Madonna delle Grazie, 16/A, I-28052 Cannobio (IT).		(74) Agents: GUTMANN, Ernest et al.; S.C. Ernest Gutmann-Yves Plasseraud, 67, bld. Haussmann, F-75008 Paris (FR). (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i>
(54) Title: USE OF MELATONIN OR DERIVATIVES THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS EFFECTIVE TO COUNTERACT THE EFFECTS OF AGING		
(57) Abstract The invention relates to the use of melatonin or related active chemical compounds for the production of pharmaceutical compositions for the enhancement of resistance in a host to the effect of age.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

Use of melatonin or derivatives thereof for the production of pharmaceutical compositions effective to counteract the effects of aging.

5 The present invention relates to a method and composition for oral or systemic treatment to delay aging and prevent, reverse or delay the symptoms of age related debility, disease and cosmetic decline. More particularly the invention provides a method and composition for
10 clinically treating the physiologic changes of senescence and degenerative disease in man and other mammals by the administration of a composition containing a melatonin compound or homologue thereof in order to produce clinical improvement or maintain functional status in man and
15 animals beset by age related loss in function.

More particularly, this invention provides a composition for the physiologic, biochemical, immunologic and cosmetic improvement of biomarkers which show evidence of decline with age. The use of melatonin, through
20 stimulation of immunologic response and repair mechanisms should serve to increase resistance to infection and to degenerative diseases that are seen with progressive advanced chronologic age.

While aging is a natural event that leads to loss
25 of vigor, cosmetic change, debility and death, the rate of physiologic change that leads to the expression of age related events can be slowed by environmental and nutritional manipulation. In invertebrates and cold blooded vertebrates (poikilotherms), decreasing temperature or
30 activity which slows metabolic events delays aging. In mammals, dietary restriction in rats results in prolongation of both median and absolute survival and can restore protein synthetic and immunologic function to a more youthful range. Similar results with rejuvenation of

functional decline have been obtained in older rats and mice subjected to hypophysectomy with hormonal maintenance provided by thyroid and corticosteroids.

Age related Physiological processes and biochemical processes have been reviewed in a recent paper by R. ROZENCWAIG, B.R. GRAD, and J. OCHOA in "MEDICAL HYPOTHESES" (1987), 23, 337-352 edited by the Longman Group UK Ltd.

They recall that of this time nearly fifty enzyme induction impairments have been shown to occur during senescence (ADELMAN, R.C., "Age-dependent effects in enzyme induction - A biochemical expression of aging". Exp. Geront. 6:75, 1971). These processes are responsive to various pharmacological and nutritional changes (ADELMAN R.C., FREEMAN, C. and COHEN, B.S., "Enzyme adaptation as a biochemical probe of development and aging". In: Advances in Enzyme Regulation, Weber, G. Ed. Volume 10, Oxford and New York, Pergamon Press, 365, 1972). Critical among these for the aging process is the linear decline during senescence of the pineal enzyme, N-acetyl transferase (NAT), resulting in the decline of melatonin (REITER, R.J., RICHARDSON, B.A., JOHNSON, L.Y., FERGUSON, B.N., DINH, D.T., "Pineal melatonin rhythm: Reduction in aging Syrian hamsters". Science 210:1372, 1980).

Ideas were presented by the authors, as well as others earlier, that the pathophysiological changes associated with the aging process were connected with a decline of pineal activity, particularly pineal melatonin. Thus aging of the pineal gland itself would lead to a predictable chain of events responsible for the phenomena of aging. Having recalled that "pineal rhythmicity is the only biological clock synchronized with a time dimension, which also has the capacity to repair and rejuvenate the organism" and "since the pineal gland's action to delay

development is known, it is not surprising that it would also act to delay developmental senescent changes and extend the lifespan". They concluded that a possibility of the reversal of senescence called for exploration and that "this may require replacement of melatonin along with
5 other hormones in order to achieve a more youthful endocrine balance and homeostasis, and consequently a possible repair of the body as a whole".

The invention is concerned with compounds prepared for use in a treatment that will delay or reverse the
10 aging process. This can be understood if age is seen as a distinct syndrome governed by a neuroendocrine clock with beyond puberty and sexual maturity programs the onset of debility, impaired functional capacity, change in appearance, and degenerative disease leading to dependency
15 and death.

This invention utilizes melatonin or related compounds to reset the neuroendocrine clock that governs aging. Melatonin even when given alone in appropriate circadian fashion, parenterally, or preferably orally or
20 rectally, stimulates immune and cellular responses involved in homeostatic and eustatic repair mechanisms that prolong the physiologic integrity of the body. Related homologues of melatonin, as defined hereinafter, are deemed to possess the same properties.

Melatonin and related homologues thus appear as biologic transducers which alter neuroendocrine, neurohypophyseal (pituitary) function, which prolongs the physiologic juvenile state and maintains youthful function and vigor beyond the median or absolute limits of the
30 usual pattern of age related decline in function and survival. The pharmacological assays whose results are reported hereafter provide evidence that restoration of melatonin levels in vivo to their circadian values by external administration thereof under the above indicated
35

conditions, particularly at a time between sunset and then where the subject goes to sleep, also entails the prolongation of the period of effective sexual maturity -- thereby delaying senescence, cosmetic change, debility and death. By further stimulating immune responsiveness and resistance to disease, thus blocking the entry of acute and chronic infection and associated degenerative disease which occur with increasing chronologic age, melatonin and related homologues appear as efficient products for delaying the onset of senescence and prolonging the period of youthful survival.


The invention thus relates to the preparation of drug compositions which contain melatonin or related homologues for use in a systemic treatment utilizing melatonin and related homologues that will delay, attenuate and remit functional impairment or cosmetic changes associated with advanced chronologic age.

Particularly melatonin is suitable as an active principle of a prophylactic or therapeutical drug in all age-related diseases, in particular in those syndromes and derangements consequent to age-dependent alterations of central or peripheral neuroendocrine functions like, e.g., hypothyroidism, hypercholesterolemia, senile diabetes, arteriosclerosis, hypertension, hypogonadism, hypocortico-surrenism, Parkinson disease, post-menopausal or senile osteoporosis, anemias, immunological deficiency in responding to bacterial and viral pathogens. Most of those syndromes represent the so-called "metabolic aging" which can be delayed by administration of exogenous melatonin to enhance the levels of melatonin at night in the treated subjects.

The invention thus relates to the production of pharmaceutical compositions for use as anti-aging agents, whose active component consists of melatonin itself. The invention also contemplates the use of chemical homologues for the same purpose. There should be

5

mentioned more particularly the class of compounds which can be represented by the general formula :



10


in which :

- n is 1 or 2,
- R_1 and R_2 , identical or different from each other, are -H, $-NH_2$, $-COOH$, $-OH$, acyl, $-NH$ -acyl or alkoxy, said acyl or said alkoxy comprising from 1 to 4 carbon atoms,
- X is $-OH$ or alkoxy comprising from 1 to 4 carbon atoms,
- Y is -H, $-OH$ or $-NH_2$.

20

Preferred compounds for use in the compositions of the invention are those in which Y is hydrogen and X is methoxy. The most preferred compound is melatonin itself, the formula of which is

25



35

Other preferred compounds for use in the

compositions of the invention are :

- 5-methoxytryptamine,
- 5-methoxytryptophan,
- 5-methoxytryptophol,
- 5 - 5-methoxyindole-3-acetic acid,
- 6-hydroxy-melatonin.

These compounds can be obtained by synthetic processes, general methods of manufacture which can be derived from those published by J. SUPNIEWSKI et al, "Synthesis of melatonin 5-methoxy-N-acetyltryptamine", 10 published in Bull. Acad. Polon. Sci. Biol., 8, pp.479-481, 1960, or Mashkovsky et al, in Farmakol. Toksikol., 26, n° 1, 10, 1963, said methods being of course in each case adapted to the particular compound sought.

15 Further details will appear from the following disclosure of examples which establish the capability of melatonin and related homologues to effectively enhance the resistance of a host against the effects of aging, as manifested by the prolongation of life in aging mice under 20 the conditions disclosed hereafter.

Experiments were initiated in 1985 in which groups of C57BL/6J inbred male mice, aged 575 days (10 mice per group), were given melatonin (10 µg/ml) in the drinking water while the controls received tap water containing the 25 same amount of absolute ethanol used to prepare melatonin stock solution (1 ml ethanol in 10 liters tap water). The drinking water with or without melatonin was given at 6 p.m. and removed at 8.30 a.m. The drinking water was changed twice weekly. Starting at 5 months after initiation of the nocturnal, oral melatonin treatment, when the 30 mice reached two years of age, a striking difference of body weight and of general body and pelage conditions started to be evident. Although some of the mice died earlier in both groups, the majority of the surviving mice

treated with melatonin maintained their optimal body weight until 26 to 32 months of age (35.8 ± 4 grams) while the untreated mice lost progressively weight and were all dead within 29 months of age. Average body weight of the control mice at 27 months of age was 27.8 ± 4 grams.

The last melatonin-treated mouse died at 3 years of age. These data though preliminary make it evident that melatonin treatment of aging mice prolonged their life or circa 20 percent (average 6 months longer). The life span of melatonin-treated mice was 931 ± 80 days while that of control mice was 755 ± 81 days ($p < 0.01$).

These remarkable effects of cyclical, chronic oral administration of melatonin alone on the aging process and their dimension surpassed any expectation one could have had upon initiating these assays. In fact, evidently and as judged by the prolonged objective, youthful appearance of the mice (vigor, fur quality and brightness, motility, weight), melatonin not only prolonged the life of the animals, but also exerted an extraordinary positive action on their performance and reversed or delayed the symptoms of age-related debility, disease and cosmetic decline in a dramatic fashion.

It is therefore striking that melatonin alone administered exogenously appears to act as a substantial substitute for the highly complex functions of the pineal gland which are reduced in a living host under the effects of aging, and in particular that exogenous melatonin appears capable of slowing down the progressive decline of absolute or cyclic melatonin synthesis in the pineal gland consequent to a variety of factors involving its metabolic precursors and/or enzymatic pathway leading, from serotonin, to its optimal and individually-shaped night release. This "metabolic aging" may in fact be corrected and even reversed by exogenous chronic, cyclic restoration of an optimal night periodicity of melatonin level in the aged, as shown in rejuvenated mice of the above disclosed

experiment.

The additional data hereafter demonstrate the regulatory effects of systemic, exogenous melatonin on the regulation of the hypothalamic-pituitary-adrenal-gonadal-thyroid axes.

It can be seen (Table 1) that chronical treatment with melatonin in the drinking water in aging mice elevates the levels of T3 (tetraiodotyronine) and T4 (thyroxine) in their peripheral blood and corrects thus ageing-related thyroid dysfunction or lowered function.

Table 2 shows that levels of cholesterol, triglycerides and phospholipids are significantly increased in the peripheral blood of 23 month-old, aging C57BL/6 mice which had been pinealectomized at the age of four months. Also the chronical treatment with night melatonin in aging mice corrects the aging-related increase of lipids in blood (not shown here). It follows that the increase of the production of thyroid hormones induced in vivo by exogenous melatonin should also be accompanied by an improved degradation of cholesterol, triglycerides and phospholipids and by detoxification effects at the liver level, all these beneficial effects resulting in a slowing down of the aging process.

TABLE 1

Chronical night treatment with melatonin in the drinking water elevates levels of T3 and T4 and of T4/T3 ratio in the blood of aging mice.

5	Strain of mice	No	Age * (months)	Months of melatonin treatment	T3	T4	T4/T3
10	C57BL/6 female untreated	9	22	-	0.614± 0.186	30.00± 14.03	48.86
	C57BL/6 female melatonin- treated	9	22	5	0.691± 0.077 (+11%)	37.50 5.65 (+20%)	54.27 (+10%)
15	C3H/He female untreated	7	23	-	0.531± 0.225	18.5± 8.1	34.84
20	C3H/He female melatonin- treated	6	23	3	0.664± 0.137 (+25%)	28.2± 0.8 (+34%)	42.47 (+18%)

Details are indicated in the text. The mice were bled at 11 am from the retroorbital plexus under acute ether anaesthesia. T3 and T4 was measured by radioimmunoassay in the serum of individual mice.

* When bleeding and measurements of T3 and T4 were performed.

30

35


10

TABLE 2

Pinealectomy produces an increase of lipid levels in the peripheral blood of aging C57BL/6 female mice.

Groups	No of mice	Age* (months)	Months after pinea-lectomy	Choles-terole (nmol/l)	Trigly-cerides (nmol/l)	Phospho-lipids (nmol/l)
5						
Pinea-lect.	8	23	19	1.91 ± 0.35 (+30%)	1.03 ± 0.28 (+26%)	2.21 ± 0.27 (+21%)
10						
Sham-operated	6	23	19	1.47 ± 0.11	0.82 ± 0.13	1.82 ± 0.60

15 * When bleeding and measurements of lipids were performed



Thus melatonin and related homologues may particularly be used to combat or slow down the effects of aging, accordingly aging itself.

The invention thus concerns pharmaceutical compositions containing melatonin, or an homologue thereof, prepared with a view of preventing aging in mammals, such pharmaceutical compositions further containing a pharmaceutical vehicle suitable for the chosen administration route. These compositions may of course also include other active principles which are likely, in association or synergetically, to interact with melatonin or the relevant homologue to achieve the effect sought.


Effective use of melatonin or its chemical homologues with a view of reinforcing the defenses of the mammal host against aging, comprises administering to the latter an effective dose of said melatonin or homologues, in one of the administration forms which have been mentioned above, preferably from sunset, or a little earlier, say from 4 P.M. up to the time where the host goes to sleep. Examples of daily doses capable of inducing an effect, range from 0.1 to 200 mg, preferably from 0.5 to 50 mg per kg of body weight, when the administration is effected by the oral or rectal route, or again from 0.05 to 10 mg, preferably from 1 to 5 mg per kg of body weight, when administered by the parenteral route.

These unit doages are of course only indicative as the actual dosages should be adjusted by the clinician for each person individually, among other factors according to his own age and degree of clinical senescence. Administrations may be chronical or cyclic over periods, e.g. from one to four weeks separated by time intervals without treatment.

12

CLAIMS

1. Use of a compound hereafter defined for the production of pharmaceutical compositions effective to counteract the effects of aging, wherein said compound has the following formula :




in which :

- n is 1 or 2,
 - R₁ and R₂, identical or different from each other, are -H, -NH₂, -COOH, -OH, acyl, -NH-acyl or alkoxy, said acyl or said alkoxy comprising from 1 to 4 carbon atoms,
 - X is -OH or alkoxy comprising from 1 to 4 carbon atoms,
 - Y is -H, -OH or -NH₂.
2. The use of claim 1, wherein said compound is melatonin.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP 88/01059

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC: IPC4: A 61 K 31/40, C 07 D 209/14		
II. FIELDS SEARCHED <div style="text-align: center;">Minimum Documentation Searched *</div>		
Classification System	Classification Symbols	
IPC4	A 61 K; C 07 D	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
X,P	Immunology Letters, Vol. 16, December 1987 W. Pierpaoli et al.: "Melatonin: a principal neuroimmunoregulatory and anti-stress hormone: its anti-aging effects ", see page 355 - page 362 see particularly pages 358, 360 --	1-2
X	US, A, 3 642 994 (FERNANDO ANTON-TAY) 15 February 1972, see especially column 2, lines 34-39 --	1-2
X	WO, A, 8605093 (CELLENA (CELL ENGINEERING) A.G.) 12 September 1986, see page 3, last paragraph and page 18 --	1-2
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: 10</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 28th February 1989	Date of Mailing of this International Search Report 7 MAR 1989	
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer  P. VAN DER PUTTEN	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to C/a - No
------------	--	----------------------

A	GB, A, 1 493 941 (LUIGI DI BELLA ET AL.) 30 November 1972, see page 1 last paragraph -- -----	1-2
---	---	-----

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

PCT/EP 88/01059

SA

25603

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office (EPO) file on 12/01/89.
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 3 642 994	15/02/72	NL-A- 7106993	29/11/71
		DE-A- 2125427	09/12/71
		FR-A-B- 2100679	24/03/72
		GB-A- 1356965	19/06/74
		CA-A- 960966	14/01/75
		BE-A- 767566	24/11/71
WO-A- 8605093	12/09/86	AU-D- 56267/86	24/09/86
		EP-A- 0214254	18/03/87
		JP-T- 62502118	20/08/87
		US-A- 4746674	24/05/88
GB-A- 1 493 941	30/11/72	BE-A- 824022	16/04/75
		NL-A- 7417046	02/07/75
		FR-A- 2255897	25/07/75
		DE-A- 2435365	29/01/76
		CH-A- 625218	15/09/81